UNITED STATES
                        SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549

                                   FORM 10-K/A

                                 Amendment No. 1


[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934
                   For the fiscal year ended December 31, 2013

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

           For the transition period from ___________ to ___________

                       Commission File No. 333-192374


                             SIGNAL ADVANCE, INC.
             (Exact name of registrant as specified in its charter)



                                    Texas
         (State or Other Jurisdiction of Incorporation or Organization)

                                     8731
             (Primary Standard Industrial Classification Number)

                                  76-0373052
                     (IRS Employer Identification Number)

                             2520 County Road 81
                            Rosharon, Texas 77583
                               (713) 510-7445
          (Address and telephone number of principal executive offices)


Securities registered pursuant to Section 12(b) of the Act:  None

Securities registered pursuant to Section 12(g) of the Act:  None













                                      1
<PAGE>

Indicate by check mark whether the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.  Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act.  Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for shorter period that the
registrant as required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.  Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, or a non-accelerated filer. See definition of
"accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange
Act.(Check one)

      Large accelerated filer  [ ]          Accelerated filer          [ ]
      Non-accelerated filer    [ ]          Smaller reporting company  [X]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act).  Yes [ ] No [X]

As of December 31, 2013, the registrant had 9,520,409 shares of common stock
issued and outstanding. No market value has been computed based upon the fact
that no active trading market has been established as of December 31, 2013.



                               EXPLANATORY NOTE

Signal Advance, Inc. (the "Company") is filing this Amendment No. 1 (this Form
10-K/A) to its Annual Report on Form 10-K for the fiscal year ended December
28, 2013 (the Original Form 10-K), as originally filed with the Securities
and Exchange Commission on March 5, 2014. This Form 10-K/A, which replaces in
its entirety the Original Form 10-K, is being filed solely for the purpose of
correcting minor typographical and other formatting errors found in the
Original Form 10-K. The XBRL files are not being included as there were no
revisons the financial data therein.

This Form 10-K/A reflects information as of the original filing date of the
Original Form 10-K, does not reflect events occurring after that date and does
not modify or update in any way disclosures or forward-looking statements made
in the Original Form 10-K.






                                      2
<PAGE>
TABLE OF CONTENTS


                                    PART I

   ITEM  1     Description of Business....................................4
   ITEM  1A    Risk Factors...............................................8
   ITEM  2     Description of Property....................................8
   ITEM  3     Legal Proceedings..........................................8
   ITEM  4     Submission of Matters to a Vote of Security Holders........8

                                    PART II

   ITEM  5     Market for Common Equity and Related Stockholder Matters...9

   ITEM  6     Selected Financial Data...................................10
   ITEM  7     Management's Discussion and Analysis of Financial
                Condition and Results of Operations......................10
   ITEM  7A    Quantitative and Qualitative Disclosures about
                Market Risk..............................................14
   ITEM  8     Financial Statements and Supplementary Data...............14
   ITEM  9     Changes In and Disagreements with Accountants
                on Accounting and Financial Disclosure...................27
   ITEM  9A(T) Controls and Procedures...................................27

                                    PART III

   ITEM 10     Directors, Executive Officers, Promoters and Control
                Persons of the Company...................................29
   ITEM 11     Executive Compensation....................................31
   ITEM 12     Security Ownership of Certain Beneficial Owners and
                Management and Related Stockholder Matters...............30
   ITEM 13     Certain Relationships and Related Transactions............33
   ITEM 14     Principal Accountant Fees and Services....................33

                                    PART IV

   ITEM 15     Exhibits..................................................33





















                                      3
<PAGE>
                                    PART I

Item 1. Description of Business

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements. These statements
relate to future events or our future financial performance. These statements
often can be identified by the use of terms such as "may," "will," "expect,"
"believe," "anticipate," "estimate," "plan," "approximate" or "continue," or
the negative thereof. We intend that such forward-looking statements be
subject to the safe harbors for such statements. We wish to caution readers
not to place undue reliance on any such forward-looking statements, which
speak only as of the date made. Any forward-looking statements represent
management's best judgment as to what may occur in the future. However,
forward-looking statements are subject to risks, uncertainties and important
factors beyond our control that could cause actual results and events to
differ materially from historical results of operations and events and those
presently anticipated or projected. We disclaim any obligation subsequently
to revise any forward-looking statements to reflect events or circumstances
after the date of such statement or to reflect the occurrence of anticipated
or unanticipated events. Unless the context requires otherwise, the terms
'Company,' 'SAI,' 'SA,' 'we,' 'our,' and 'us' refer to Signal Advance Inc.,
a Texas corporation formed on June 4, 1992.

OVERVIEW:  Signal Advance, Inc. (SAI) is a technology development firm that
has been developing its proprietary Signal Advance Technology (SAT) which
may significantly reduce signal detection delays associated with a variety
of physical sensors and thereby improve performance in control, intervention
and signal transmission systems.  The Company has developed and tested SA
circuit designs and discrete circuit prototypes for a range of signals.

CHALLENGE:  In interventional medical devices or non-medical responsive
control and signal transmission systems, delays in detection, processing and
response to various signals negatively affects overall performance. For
certain types of biomedical signals (e.g. heart, brain) the greater the delay
in responding to anomalous signals, the more difficult it is to successfully
intervene in order to contain or limit a pathological process such as cardiac
fibrillation or an epileptic seizure.  The earlier the intervention is
initiated, the greater the probability of success. In non-medical applica-
tions (e.g. industrial process, equipment, engine control, military), control
response signal transmission delays impact performance effecting safety,
product yield, fuel efficiency and waste/emissions. In military applications,
signal detection and response delays affect reaction effectiveness.

SOLUTION:  In most electronic circuits, signal output is delayed relative to
the input as it traverses the circuitry. In an SA circuit, the output signal
is advanced in time relative to the input, thus the term 'Signal Advance'.
In other words, the output signal emerges before the complete detection of
the input signal.

The temporal advance achieved using SAT can potentially offset signal
detection and processing delays and, thereby, improve response time. Further,
we believe that SAT could be implemented in conjunction with other approaches
(e.g. faster electronics) to further reduce these response delays to further
improve system performance. SAT may also enable the development of novel
signal transmission, and control or interventional approaches.

                                      4
<PAGE>
Prototype SAT circuit designs were used to temporally-advance the detection
of analog test signals and bioelectric (cardiac) signals in a dissertation
study completed by Dr. Hymel (SAI Founder/president) at the University of
Texas Health Science Center in the Texas Medical Center, Houston Texas. The
study results were later published in a peer-reviewed feature article which
appeared in the IEEE Circuits and Systems magazine.

MARKET:  SAI identified multiple classes of sensors with signal characteris-
tics which may be suitable for the application of SAT, and thus, a variety of
potential licensing targets. The markets/industries include medical (e.g.
cardiac rhythm management, neurostimulation) and commercial, industrial,
communications, transportation and military applications (e.g. process
control, signal transmission, engine control, vehicular/flight control,
accident avoidance, and weaponry).

In interventional medical devices, SAT could reduce response delays, and
improve performance. The improved performance translates directly to
increased value, providing a significant opportunity for revenue generation.
Examples of non-medical applications include transportation, in which SAT
could improve accident avoidance, safety/security, engine performance and
vehicular control, and thus improve fuel economy and save lives. In high
performance aircraft engines, SAT might increase stability, reduce stall
margins - improving performance and fuel efficiency. Industrial examples
include improved compressor performance and increased petrochemical yields.
In military applications, SAT could enhance response effectiveness

The addressable markets are estimated to be in the billions of dollars. As
with any new or disruptive technology, recognition and acceptance will gain
momentum over time.

INTELLECTUAL PROPERTY:  The following table lists the patent applications
and issued patents:

   Patent Office       Patent or Appl. No.           Status
  ----------------    --------------------------    --------------------
   United States       8452544                       Issued May 2013
   China               ZL 200880015288.2             Issued Nov. 2012
   Europe              EP 08 75 4879.8               Under examination
   Mexico              MX/A/2009/00921               Under examination
   India               3465/KOLNP/2009               Not yet examined

Additional patent submissions related to specific applications, SA circuit
configurations, and signal processing techniques to improve signal fidelity
are being drafted.

COMPETITION:  Indirect competition exists as in the form of ever faster
electronics used to improve signal detection and processing performance. In
addition, alternate control strategies, (e.g. predictive feedback and feed-
forward) are often used to improve performance but also have significant
drawbacks. Faster electronics alone will reduce, but never eliminate,
circuit delays. For a number of applications, some of these techniques may
be adequate. SAT, used in conjunction with all of these methods, could
further improve performance.





                                      5
<PAGE>
REVENUE GENERATION:  While the addressable markets are in the billions, it is
expected that many licensees will require exclusivity which would limit SAI
to a single license in a given application area. Therefore, SAI will target
multiple application areas to generate revenue. Revenue is generated by: 1)
licensing intellectual property to product manufacturers, 2) consulting with
licensees on implementation of the technology in target applications, and 3)
participating in joint ventures.

MARKETING STRATEGY:  To gain exposure and acceptance of SAT, the Company will
participate in trade shows, present in scientific and technical meetings and
publish application-specific articles.  SAI's marketing approach includes the
following steps: 1) identify application targets, 2) develop application-
specific SAI circuitry, 3) demonstrate performance improvement, 4) protect
the intellectual property, 5) approach target manufacturer(s) and 6) secure
licensing/consulting agreements.

Target application selection is based on: 1) intervention/control impact,
2) signal characteristics, 3) market size, 4) supplier market share,
5) competition and 6) regulations.

The initial approach is to identify applications and protect IP; then consult
with market-specific clients to develop SAT for their specific application
and demonstrate improved product performance. Later strategy will shift
development costs to the client.

PROGRESS:  The Company has developed proprietary Signal Advance technology
which operates on broadband analog signals (over a specified frequency range)
with little signal distortion. Prototype SA circuits have been developed for
various application-specific signals and a number of SA circuit designs have
been tested using a range of analog test signals. The company is located near
the Texas Medical Center in Houston and has broad contacts in a number of its
research institutions.

SAI has initiated collaborations with private entities and research institu-
tions to protect its intellectual property, further develop/refine SAT,
embody in microelectronics (integrated circuitry), and test for improved
performance in biomedical applications by the use of SAT. The collaborations
terms are not yet established, however, the company expects to assume the
costs to develop/refine SAT and its microelectronic implementation as well as
intellectual property protection. Collaborations related to the use of SA
technology in specific biomedical applications are likely to be funded
through research grants or take the form of joint ventures.

VALIDATION/RECOGNITION:

- Scientific:  Prototype SA circuit design was tested using a range of
   simulated test signals as well as bioelectric (cardiac)  signals. The
   results were reviewed and confirmed by University facility (including
   Ph.D. physicists and engineers). This study resulted in completion of a
   successful doctoral study, by the Company's President, Dr. Hymel, at the
   University of Texas Health Science Center at Houston in the Texas Medical
   Center (2010);

- Technical:  A peer-reviewed feature article summarizing the technology,
   study results, and broad range of potential SAT applications was published
   in the IEEE Circuits and Systems Magazine in 2011;



                                      6
<PAGE>
- Commercial:  SAI was awarded first place in the 2011 Goradia Innovation
   Prize competition. The selection was based on the: 1) commercial potential
   of the technology, 2) soundness of the business plan, 2) potential for job
   growth within the region, and 4) likelihood of significant long-term
   success.

- Innovation:  The Intellectual Property Section of the Oklahoma Bar Assoc-
  iation named Dr. Chris Hymel, the company's president, the 2012 Innovator
  of the Year for his development work on Signal Advance technology.

REVENUE GENERATION: The Company plans to continue to refine and develop SAT,
demonstrate improved performance in targeted applications, pursue related
intellectual property protection and begin to commercialize the technology
through licensure.  The Company is still developing and refining its pro-
prietary technology, thus, SAI has not yet sold any products or licensed the
technology. The company is not yet profitable, currently lacks sufficient
capital to generate revenue or operate the business in a profitable manner
and has not generated sufficient revenues to fund planned R&D, marketing and
intellectual protection in the near-term.  As such, SAI continues to rely
upon capital investment to cover the projected costs of executing the
Company's business plan and effectively commercialize its proprietary Signal
Advance technology.

BROAD RISKS AFFECTING THE COMPANY:  The Company is subject to numerous risks,
which are more fully discussed in the section of this prospectus entitled
'Risk Factors'.  Some of the more significant risks included the following:

- The Company is undercapitalized and has limited liquidity.
- The Company is in the development/early commercialization stage.
- The technology is novel and thus requires recognition and acceptance in
   various markets.
- If the Company does not successfully license its technology, it may never
   achieve profitability.
- As a result of the industry competition, the Company may not gain enough
   market share to be profitable.
- If the Company fails to protect its proprietary technology, its competitive
   position may be impaired.
- There will be a limited trading market for the Company's common stock
- The market price of our common stock may fluctuate significantly and may
   decline.

EMERGING GROWTH COMPANY STATUS: The Company qualifies as an 'emerging growth
company' as defined in Section 2(a)(19) of the Securities Act of 1933 and, as
such, is allowed to provide in this prospectus more limited disclosures than
an issuer that would not so qualify. Furthermore, for as long as we remain an
emerging growth company, we will qualify for certain limited exceptions from
investor protection laws such as the Sarbanes-Oxley Act of 2002 and the
Investor Protection and Securities Reform Act of 2010. Unlike other public
companies, we will not be required to:

- Provide an auditor's attestation report on management's assessment of the
   effectiveness of our system of internal control over financial reporting
   pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002;
- Comply with any new requirements adopted by the Public Company Accounting
   Oversight Board (PCAOB), requiring mandatory audit firm rotation or a
   supplement to the auditor's report in which the auditor would be required
   to provide additional information about the audit and the financial
   statements of the issuer;

                                      7
<PAGE>
- Comply with any new audit rules adopted by the PCAOB after April 5, 2012,
   unless the Securities and Exchange Commission determines otherwise;
- Provide certain disclosure regarding executive compensation required of
   larger public companies; or
- Obtain shareholder approval of any golden parachute payments not previously
   approved.

We will cease to be an 'emerging growth company' upon the earliest of:

- When we have $1.0 billion or more in annual revenues;
- When we have at least $700 million in market value of our common units
   held by non-affiliates;
- When we issue more than $1.0 billion of non-convertible debt over a
   three-year period; or
- The last day of the fiscal year following the fifth anniversary of our
   initial public offering.

In addition, Section 107 of the JOBS Act also provides that an emerging
growth company can take advantage of the extended transition period provided
in Section 7(a)(2)(B) of the Securities Act for complying with new or revised
accounting standards. In other words, an emerging growth company can delay
the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We are electing to take advantage of
the extended transition period, and thus, we will not be required to comply
with new or revised accounting standards on the relevant dates on which
adoption of such standards is required for non-emerging growth companies.

CORPORATE INFORMATION:  Our principal executive offices are located at 2520
County Road 81, Rosharon, Texas 77583. Our website is www.signaladvance.com.


Item 1A.  Risk Factors

Not applicable to smaller reporting companies.


Item 2.  Description of Property

We do not own any real estate or other properties.


Item 3.  Legal Proceedings

We know of no legal proceedings to which we are a party or to which any of
our property is the subject which are pending, threatened or contemplated or
any unsatisfied judgments against us.


Item 4.  Submission of Matters to a Vote of Security Holders

None.







                                      8
<PAGE>
                                     PART II

Item 5. Market for Common Equity and Related Stockholder Matters

MARKET INFORMATION:  There is a limited public market for our common shares.
Our common shares are not quoted on the OTC Bulletin Board at this time.
Trading in stocks quoted on the OTC Bulletin Board is often thin and charac-
terized by wide fluctuations in trading prices due to many factors that may
be unrelated to a company's operations or business prospects. We cannot
assure you that there will be a market in the future for our common stock.

OTC Bulletin Board securities are not listed or traded on the floor of an
organized national or regional stock exchange.  Instead, OTC Bulletin Board
securities transactions are conducted through a telephone and computer
network connecting dealers in stocks.  OTC Bulletin Board issuers are
traditionally smaller companies that do not meet the financial and other
listing requirements of a regional or national stock exchange.

As of December 31, 2013, no shares of our common stock have traded.

NUMBER OF HOLDERS:  As of December 31, 2013, 9,520,409 issued and outstanding
shares of common stock were held by a total of 171 shareholders of record.

DIVIDENDS:  No cash dividends were paid on our shares of common stock during
the fiscal years ended December 31, 2013 and 2012. We have not paid any cash
dividends since our inception and do not foresee declaring any cash
dividends on our common stock in the foreseeable future.

RECENT SALES OF UNREGISTERED SECURITIES:  In 2011, 120,000 shares of common
stock were issued in exchange for services rendered by Directors, Officers
and consultants and cash investment of $10,000 by one of the Company's
Directors. A 4 for 1 reverse split became effective on September 1, 2011. As
such, the 'post' 4 for 1 reverse split equivalent number of shares of common
stock issued during 2011 was 30,000 shares.

During 2012, a private placement, specifically a 'rights' offering, was made
available to existing shareholders. In total, 63,250 shares of common stock
were issued to rights offering participants. In addition, 229,000 shares were
issued in exchange for services rendered.

In 2013, the Company's President was issued 1,000,000 shares per the terms
of IP assignment agreement.  In addition, 116,750 shares were issued in
exchange for services rendered.

These issuances of unregistered were exempt pursuant to Section 4(2) of the
Securities Act as these were privately negotiated transactions in which
there was no advertising and no commissions paid. Accordingly, the stock
certificates representing these shares were issued with restrictive legends
indicating that the shares have not been registered and may not be traded
until registered or otherwise exempt from registration.

PURCHASE OF OUR EQUITY SECURITIES BY OFFICERS AND DIRECTORS:  None.

OTHER STOCKHOLDER MATTERS:  None.


                                      9
<PAGE>
Item 6. Selected Financial Data

Not applicable to smaller reporting companies.


Item 7. Management's Discussion and Analysis of Financial Condition and
        Results of Operations

The following discussion should be read in conjunction with our financial
statements, including the notes thereto, appearing elsewhere in this annual
report. The following discussion contains forward-looking statements that
reflect our plans, estimates and beliefs.  Our actual results could differ
materially from those discussed in the forward-looking statements. Our
audited financial statements are stated in United States Dollars and are
prepared in accordance with U.S. Generally Accepted Accounting Principles.

                            RESULTS OF OPERATIONS

We have incurred recurring losses to date. Our financial statements have been
prepared assuming that we will continue as a going concern and, accordingly,
do not include adjustments relating to the recoverability and realization of
assets and classification of liabilities that might be necessary should we be
unable to continue in operation.



Our auditors have issued a going concern opinion as the Company has generated
insufficient revenues to fund planned R&D, marketing and intellectual
protection in the near-term. SAI will continue to rely on capital investment
to cover the projected costs to execute the Company's business plan and
commercialize its proprietary signal advance technology. We expect we will
require additional capital to meet our long term operating requirements. We
expect to raise additional capital through, among other things, the sale of
equity or debt securities. There is no assurance that the Company will be
able to raise sufficient capital which would require operations to be scaled
back accordingly.

The majority of the Company's resources are devoted to technology development
and protection of its proprietary technology. However, periodically, the
Company has accepted consulting work which is either directly related to SA
technology development or may lead to a potential future collaboration. As
such, revenues have varied significantly over the past three years.

INCOME:  In fiscal year ending 2011, the Company recognized revenue in the
amount of $80,000. The company recognized $10,313 and $2,350 in revenues 2012
and 2013, respectively.

EXPENSES:  Expenses are classified into the following four broad categories:
Depreciation, Intellectual Property Protection, Professional Services, R&D,
and Selling, General and Administrative. SAI has engaged consultants to
accomplish its goals over the last two years. Given sufficient capital, the
majority of these consultants have expressed interest in working full-time
for the Company. Professional Services includes expenses for accounting,
legal, transfer agent and director's fees. The increase seen in expenses
during the fiscal years ended December 31, 2013 and 2012 for Professional
Services reflect expenses related to the preparation to become registered
and reporting with the Securities and Exchange Commission as well as
intellectual property (IP) protection. In addition, $1,000,000 in equity was
paid to the Company's President (Signal Advance IP inventor) per the terms

                                     10
<PAGE>
of the IP assignment agreement following the achievement of the "Notice of
Allowability" milestone. Research and Development expenses reflect our on-
going efforts related to in scientific, technical and commercial validation.

Expenses for fiscal years ended December 31, 2013, 2012 and 2011, were as
follows:
                                               2013      2012       2011
                                               ----      ----       ----
General, Selling and Administrative           44,274    30,239     34,035
Intellectual Property Protection           1,038,508    58,638    121,351
professional Services                         92,009    62,517     32,237
Research and Development                      26,000    33,000     45,000
Depreciation                                   2,707     5,292      8,052

OTHER EXPENSE:  Other Expense included ($69) in 2012 from a K-1 issued from a
long term investment and impairment "write-down" related to "Available for
Sales Securities" of $1,487 and $23,500 for years ended 2012 and 2011.

                        LIQUIDITY AND CAPITAL ASSETS

CURRENT ASSETS:  As of December 31, 2013, the Company had cash and cash
equivalents of $12,918 and negligible "Available for Sale Securities". These
assets are used as working capital to execute the Company's business plan.
As such, the Company requires additional capital through debt or equity
financing to fund operations over the next 12 months.

Fixed assets (office/laboratory equipment) were $4,607 and $8,887, for years
ended December 31, 2012 and 2011, respectively, and $2,924 as of December 31,
2013, due to depreciation expense.

OTHER ASSETS:  In fiscal year ended December 31, 2013, 2012 and 2011, signi-
ficant resources were applied to intellectual property (IP) acquisition and
protection. This includes: 1) installment due per the terms of the assign-
ment agreement. 2) responses to preliminary searches and initial office
actions resulting from the international filings, 3) preparation/submission
of amendments and additional disclosures in the US Patent and Trademark
Office (USPTO) as well as the Chinese, European and Mexican patent offices
and 4) reviews of, and responses to, office actions by the U.S., Chinese,
European and Mexican patent offices and 5) issuance and annual renewal fees.
Patents have issued in China (Nov. 2012) and in the US (May 2013).

All costs associated with IP protection have been expensed. IP acquisition
and protection costs totaled $58,638 and $121,351, respectively, in years
ended December 31, 2012 and 2011, and $1,038,508 the year ended December 31,
2013. Further discussion regarding the intellectual property can be found in
Note B - Intellectual Property, starting on page 23 (F8 of the Financial
Statements and Supplementary Information).

Results from a single long term investment were discussed previously under
'Other Expense'. Available for sale securities lost most of their value
decreasing from $25,000 when acquired in 2011 to $13 by September 30, 2013.

LIABILITIES:  Liabilities include a short-term loan from its President
totaling $118,406 as of December 31, 2013. Further, a trade payable for
compensation due the Company president, of $120,000 at year-end 2011 was
converted to equity in 2012.


                                     11
<PAGE>
SHAREHOLDERS' EQUITY:  Accumulated deficit totaled $4,233,452, $3,057,721 and
$4,145,313 for years ended December 31, 2011, 2012 and 2013, respectively. In
2011, following shareholder approval, the board executed a one for four (1/4)
reverse split of the common stock. The shares issued and outstanding as of
December 31, 2011, 2012 and 2013, totaled 8,111,409, 8,403,659 and 9,520,409,
respectively.

OFF-BALANCE SHEET TRANSACTIONS:  There are no off-balance sheet items, all
transactions are in U.S. dollars, and SAI is not currently subject to
currency fluctuations or similar market risks.

                       SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS:  The Company considers all highly liquid invest-
ments purchased with an original maturity of three months or less to be cash
equivalents.

AVAILABLE FOR SALE SECURITIES:  The Company holds certain investments that
are treated as available-for-sale securities and stated at their fair market
values. All investments are available for current operations and are classi-
fied as other assets in the balance sheet. Realized gains and losses are
determined by the specific identification method and are included in 'Other
Income (Loss)' in the income statement.

RESEARCH AND DEVELOPMENT:  Research and development expenses are expensed as
incurred until technological feasibility can be determined. Upfront and
milestone payments made to third parties in connection with research and
development collaborations are expensed as incurred up to the point of
regulatory approval, marketability, licensing, lease, or sale when the net
present value and useful life is able to be determined. Costs associated with
intellectual property protection have been expensed until such time as the
useful can be determined, at which time, amounts capitalized will be included
in intangible property, less the net of accumulated amortization.

REVENUE RECOGNITION:  Revenue is not be recognized until it is realized or
realizable and earned. An extended discussion regarding the sources of
revenue expected as well as how revenue from these sources will be recognized
can be found under 'Revenue Recognition' beginning on page 22 (F7 of the
Financial Statements and Supplementary Information).

PROPERTY, PLANT AND EQUIPMENT:  Fixed Assets (land, buildings and equipment)
are carried at cost less accumulated depreciation. Depreciation is based on
the estimated service lives of depreciable assets and is provided using the
Modified Accelerated Cost Recovery System (MACRS) method. In the case of
disposals, assets and related depreciation are removed from the accounts, and
the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES:  The Company takes an asset and liability approach to financial
accounting and reporting for income taxes. Differences between the financial
statement and tax basis of assets and liabilities is determined annually.
Deferred income tax assets and liabilities are computed for those differences
that have future tax consequences using the currently enacted tax laws and
rates that apply to the periods in which they are expected to affect taxable
income. Valuation allowances are established, if necessary, to reduce the
deferred tax asset to the amount that will assure full realization.
As of December 31, 2013, the Company recorded a valuation allowance that
reduced its deferred tax assets to zero.

                                     12
<PAGE>
CONCENTRATIONS OF CREDIT RISK:  Financial instruments which may subject the
Company to significant concentrations of credit risk consist primarily of
investment securities. Investment securities are exposed to various risks,
such as interest rate, market and credit risks. Due to the level of risk
associated with certain investment securities, it is reasonably possible that
changes in the values of investment securities can occur in the near term and
that such change could materially affect the amounts reported in the
financial statements.

IMPAIRMENT:  The Company amortizes intangible assets over their estimated
useful lives unless such lives are deemed indefinite. Amortized intangible
assets are tested for impairment based on undiscounted cash flows, and, if
impaired, written down to fair value based on either discounted cash flows
or appraised values. Intangible assets with indefinite lives are tested
annually for impairment and written down to fair value as required.

DEFERRED TAX ASSET:  A valuation allowance was not recognized for the full
amount of the deferred tax asset because, based on the weight of available
evidence, it is more likely than not that some portion or the entire
deferred tax asset will not be realized.

NET EARNINGS PER SHARE:  Basic earnings per share is computed by dividing
net income available to common shareholders by the weighted average number
of common shares outstanding for the period.

                       PLAN OF OPERATION AND FUNDING

We expect that working capital requirements will continue to be funded
through a combination of our existing funds and further issuances of
securities. Our working capital requirements are expected to increase in
line with the growth of our business.

Existing working capital, further advances, debt instruments, and firm
commitments are expected to be adequate to fund our operations over the next
three months. We have no lines of credit or other bank financing arrange-
ments. Generally, we have financed operations to date through the proceeds of
the private placement of equity and debt instruments. In connection with our
business plan, management anticipates additional increases in operating
expenses and capital expenditures relating to: i) technology development, ii)
marketing and commercialization, and iii) intellectual property protection.
We intend to finance these expenses with further issuances of securities, and
debt issuances. Thereafter, we expect we will need to raise additional
capital and generate revenues to meet long-term operating requirements.

Additional issuances of equity or convertible debt securities will result in
dilution to our current shareholders. Also, such securities may have rights,
preferences or privileges senior to our common stock. Additional financing
may not be available upon acceptable terms, or at all. If adequate funds are
not available or are not available on acceptable terms, we may not be able to
take advantage of prospective new business endeavors or opportunities, which
 could significantly and materially restrict our business operations.


MATERIAL COMMITMENTS:

Payments due by Period:   Total   <1 year   1-3 years   3-5 years   >5 years
                         ------   -------   ---------   ---------   --------
Office Lease (per year)  $8,400    $8,400

                                     13
<PAGE>
PURCHASE OF SIGNIFICANT EQUIPMENT: We do not intend to purchase any
significant equipment during the next twelve months.

                                GOING CONCERN

The independent auditors' report accompanying our Financial Statements and
Supplementary Information for years ended December 31, 2013, 2012 and 2011
contains an explanatory paragraph expressing substantial doubt about our
ability to continue as a going concern. The financial statements have been
prepared "assuming that we will continue as a going concern," which
contemplates that we will realize our assets and satisfy our liabilities and
commitments in the ordinary course of business.


Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Not applicable to smaller reporting companies.


Item 8. Financial Statements and Supplementary Data


                             SIGNAL ADVANCE, INC.

             FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

                Years Ended December 31, 2013, 2012 and 2011



                               TABLE OF CONTENTS
                                                                       Page No.

ACCOUNTANT'S REPORT.......................................................F 1

FINANCIAL STATEMENTS

   Balance Sheet..........................................................F 2

   Statements of Income and Retained Earnings (Accumulated Deficit).......F 3

   Statement of Cash Flows................................................F 4

   Statement of Changes in Shareholders' Equity...........................F 5

   Notes to Financial Statements.......................................F 6-11

SUPPLEMENTARY INFORMATION

   Schedule of General, Selling and Administrative Expenses..............F 11








                                     14
<PAGE>
                              Bobby J. Hutton
                        Certified Public Accountant
                            4824 Courtside Drive
                            Fort Worth, TX 76133

            Report of Independent Registered Public Accounting Firm
            -------------------------------------------------------
The Board of Directors
Signal Advance, Inc.
2520 CR 81
Rosharon, TX  77583

We have audited the accompanying balance sheet of Signal Advance, Inc. (a
Texas Corporation) as of December 31, 2013, 2012 and 2011, and the related
statements of income and retained earnings (accumulated deficit), cash flows
and changes in stockholders' equity for the years then ended. The financial
statements are the responsibility of management. Our responsibility is to
express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). These standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatements. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statements presentation. We believe that
our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Signal Advance, Inc. as
of December 31, 2013, 2012 and 2011 and the results of its operations and
its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note A in the
financial statements, the Company's operating losses raise substantial doubt
about its ability to continue as a going concern. The financial statements
do not include any adjustments that might result from this uncertainty.

Very truly yours,



Bobby J. Hutton
Certified Public Accountant

Fort Worth, Texas
January 28, 2014






                                                                          F 1

                                     15
<PAGE>

                             Signal Advance, Inc.
                               Balance Sheets
                     As of December 31, 2013, 2012, 2011



                                            2013         2012         2011
                                        -----------  -----------  -----------
ASSETS

  Current Assets
    Cash                                    11,497        8,110       12,918
                                        -----------  -----------  -----------
  Total Current Assets                      11,497        8,110       12,918
  Fixed Assets (net accumulated
     depreciation) - Note D                  3,924        4,607        8,887
  Available for Sale Securities                 13           13        1,500
     - Note C

  Long-Term Investments                     21,438       21,438       21,369
                                        -----------  -----------  -----------
TOTAL ASSETS                                36,871       34,167       44,674
                                        ===========  ===========  ===========

LIABILITIES & EQUITY

Liabilities
 Loan from Shareholder - Note F            118,406       31,303       33,269
 Trade Payable - Note G                          0            0      120,000
                                        -----------  -----------  -----------
  Total Liabilities                        118,406       31,303      153,269

 Shareholders' Equity
  Common Stock - $0 par value - Note J
    -shares issued and outstanding
       9,520,409, as of Dec. 31, 2013
       8,403,659, as of Dec. 31, 2012
       8,111,409, as of Dec. 31, 2011

  Paid-in Capital in excess of par
    Cash                                   667,101      667,101      603,851
    Services/Assets                      3,509,732    2,392,982    2,163,982
                                        -----------  -----------  -----------
  Total Capital Investment               4,176,834    3,060,084    2,767,834


  Retained Earnings (Accum. Deficit)    (3,057,220)  (2,876,429)  (2,692,255)
  Net Income                            (1,201,149)    (180,790)    (184,174)

    Total Shareholders' Equity             (81,535)       2,864     (108,595)

TOTAL LIABILITIES & EQUITY                  36,871       34,167       44,674
                                        ===========  ===========  ===========





                 See Accompanying Notes and Accountant's Report           F 2

                                     16
<PAGE>
                              Signal Advance, Inc.
        Statements of Income and Retained Earnings (Accumulated Deficit)
                  Years Ended December 31, 2013, 2012, 2011

                                            2013         2012         2011
                                        -----------  -----------  -----------
Ordinary Income/Expense

 Revenues
   Consulting                                    0        4,025       45,000
   Other Income                              2,350        6,288       35,000
                                        -----------  -----------  -----------
     Total Revenues                          2,350       10,313       80,000

 Cost of Sales                                   0            0            0
                                        -----------  -----------  -----------

 Gross Profit                                2,350       10,313       80,000

 Expenses

   General, Selling & Administrative        44,274       30,239       34,035

   Depreciation                              2,707        5,292        8,051
   Intellectual Property - Note B        1,038,508       58,638      121,351
   Professional Services                    92,009       62,517       32,237
   Research & Development                   26,000       33,000       45,000
                                        -----------  -----------  -----------
 Total Expenses                          1,203,499      189,685      240,674

     Net Ordinary Income                (1,201,149)    (179,372)    (160,674)

 Other Income/(Expense)

   Adjustment of Impairment - Note C             0        1,487       23,500
   Gain/(Loss) on Equity Investment              0         (69)           0

                                        -----------  -----------  -----------
 Total Other Income/(Expense)                    0        1,418       23,500

     Net Income                         (1,201,149)    (180,790)    (184,174)
                                        ===========  ===========  ===========













                See Accompanying Notes and Accountant's Report            F 3

                                     17
<PAGE>
                            Signal Advance, Inc.
                          Statement of Cash Flow
                 Years Ended December 31, 2013, 2012, 2011

                                            2013         2012         2011
                                        -----------  -----------  -----------
  OPERATING ACTIVITIES
    Net Income                          (1,201,149)    (180,790)    (184,174)
    Adjustments to reconcile Net
     Income to net cash provided by
     operations:
        Accounts Receivable                      0            0          109
        Depreciation                         2,707        5,292        8,051
        Non-Cash Expenses:
          Intellectual Property
            assigned in exchange
            for equity                   1,000,000            0            0
          Services rendered in
            exchange for equity            116,750      229,000       66,667
                                        -----------  -----------  -----------
  Net cash provided by
    Operating Activities                   (81,692)      53,501     (109,347)

  INVESTING ACTIVITIES
     Fixed Assets (Cost/Basis)              (2,024)      (1,012)        (607)
     Available for Sale Securities               0        1,487       (1,500)
     Long-Term Investments                       0          (69)           0
                                         -----------  -----------  -----------
  Net cash provided by
    Investing Activities                    (2,024)         407       (2,107)

  FINANCING ACTIVITIES
    Capital Investment
      (Common Stock Sales)                       0       63,250       10,000
    Loan from Shareholder                   87,103       (1,966)      (8,005)
    Trade Payable                                0     (120,000)     120,000
                                        -----------  -----------  -----------
  Net cash provided by
    Financing Activities                    87,103      (58,716)     121,995

 Net cash increase for period                3,387       (4,808)      10,540
                                        -----------  -----------  -----------
 Cash at beginning of period                 8,110       12,918        2,378

Cash at end of period                       11,497        8,110       12,918
                                        ===========  ===========  ===========

 Supplemental Disclosures

    Interest Expense                         8,901        2,704        3,942
                                        ===========  ===========  ===========





                See Accompanying Notes and Accountant's Report            F 4

                                     18
<PAGE>
                            Signal Advance, Inc.
               Statement of Changes in Shareholders' Equity
                 Years Ended December 31, 2013, 2012, 2011
<TABLE>
<CAPTION>
                   Common Stock     Additional  Net Other                   Total
                ------------------  Paid-in     Comprehensive  Accumulated  Shareholders'
                 Shares    Amount   Capital     Gain/(Loss)    Deficit      Equity
                --------- --------  ----------  -------------  -----------  -------------
<S>             <C>       <C>        <C>         <C>            <C>          <C>

Balance as of
Dec.1, 2010     8,081,409      -     2,691,167            -    (2,692,255)        (1,088)

Shares Issued      30,000      -        76,667            -            -          76,667

Net Other
Comprehensive
Gain(Loss)            -        -           -         (23,500)          -         (23,500)

Net Loss              -        -           -              -      (160,675)      (160,675)

Treasury Stock        -        -           -              -            -              -
                --------- --------  ----------  -------------  -----------  -------------
Balance as of
Dec. 31, 2011   8,111,409      -     2,767,834       (23,500)  (2,852,930)      (108,596)

Shares Issued     292,250      -       292,250            -            -         292,250

Net Other
Comprehensive
Gain(Loss)            -        -           -          (1,417)          -          (1,418)

Net Loss              -        -           -              -      (179,373)      (179,373)

Treasury Stock        -        -           -              -            -              -
                --------- --------  ----------  -------------  -----------  -------------
Balance as of
Dec. 31, 2012   8,403,659      -     3,060,084       (24,917)  (3,032,303)         2,863

Shares Issued   1,116,750      -     1,116,750            -            -       1,116,750

Net Other
Comprehensive
Gain(Loss)            -        -           -              -            -              -

Net Loss              -        -           -              -    (1,201,149)    (1,201,149)

Treasury Stock        -        -           -              -            -              -
                --------- --------  ----------  -------------  -----------  -------------
Balance as of
Dec. 31, 2013   9,520,409      -    4,176,834        (24,917)  (4,233,452)       (81,536)
                ========= ========  ==========  =============  ===========  =============
</TABLE>







  - Note J




                See Accompanying Notes and Accountant's Report            F 5

                                     19
<PAGE>
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS AND ORGANIZATION: Signal Advance, Inc. (the Company)is
currently conducting operations. Signal Advance, Inc., incorporated in Texas
on June 4, 1992, is an engineering product and procedure development and
consulting firm focused on the development of applications for emerging
technologies. The Company has significant experience in computer technology,
distributed information systems, and data acquisition and analysis systems,
medical education, intellectual property protection and medical-legal liti-
gation support. The Company has focused its resources on the improvement of
signal detection systems through the development and refinement of its
proprietary "Signal Advance" technology which has potential application in
a wide range of medical applications, as well as applications outside of
biomedicine.

CASH AND CASH EQUIVALENTS: The Company considers all highly liquid
investments purchased with an original maturity of three months or less
to be cash equivalents.

IMPAIRMENT: The Company anticipates amortizing intangible assets over their
estimated useful lives unless such lives are deemed indefinite. Amortized
intangible assets are tested for impairment based on undiscounted cash flows,
and, if impaired, written down to fair value based on either discounted cash
flows or appraised values. Intangible assets with indefinite lives are tested
annually for impairment and written down to fair value as required. No
impairment of intangible assets has been identified during any of the periods
presented.

USE OF ESTIMATES IN FINANCIAL STATEMENT PREPARATION: The preparation of the
financial statements in conformity with accounting principles generally
accepted in the United States of America requires the use of estimates and
assumptions that affect the reported amounts of assets and liabilities, the
disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. The Company's financial statements include amounts and all
adjustments that, in the opinion of management and based on management's best
estimates and judgments, are necessary to make the financial statement not
misleading. Actual results could differ from those estimates.

AVAILABLE FOR SALE SECURITIES: The Company holds certain investments that
are treated as available-for-sale securities and stated at their fair market
values. All investments are available for current operations and are
classified as other assets in the balance sheet. Unrealized holding gains
and losses are included as a component of other comprehensive income (loss)
until realized. Realized gains and losses are determined by the specific
identification method and are included in 'Other Income (Loss)' in the
income statement.









    Accompanying Notes are an Integral Part of the Financial Statements  F 6

                                     20
<PAGE>
RESEARCH AND DEVELOPMENT: Research and development costs are expensed as
incurred until technological feasibility can be determined. Upfront and
milestone payments made to third parties in connection with research and
development collaborations are expensed as incurred up to the point of
regulatory approval, marketability, licensing, lease, or sale when the net
present value and useful life is able to be determined. Payments made to
third parties subsequent to the aforementioned events will be capitalized.
Amounts capitalized for such payments will be included in other intangibles,
less the net of the accumulated amortization, once their useful lives can be
determined.

REVENUE RECOGNITION: The Company revenues are generated by: 1) Providing
consulting services; 2) Licensing intellectual property; and 3) Providing
consulting services to licensees to facilitate implementation. Revenue is
not recognized until it is realized or realizable and earned. In accordance
with ASC 605, 'Revenue Recognition,' the company recognizes as revenue the
fees charged clients as referenced below because 1) persuasive evidence of
an arrangement exists, 2) the fees charged as royalties and/or for services
are substantially fixed or determinable during the period in which services
are provided or royalties are collected, 3) the company and its clients
understand the specific nature and terms of the agreed upon transactions,
and 4) collectability is reasonably assured after services have been
rendered, or according to a royalty payment schedule.

Consulting Revenue - For revenues generated by providing engineering,
scientific and medical/legal consulting services. Services are charged at an
hourly rate and clients are charged and revenue is recognized monthly.

License Revenue - As part of the Company's business model and as a result of
the company's on-going investment in research and development, the company
plans to license and sell the rights to certain of its intellectual property
(IP) including internally developed patents, trade secrets and technological
know-how. The typical license will call for a non-refundable initiation fee,
escalating minimum royalties to be paid before a given product is marketed,
and continuing royalties based on gross sales once marketing has begun,
confirmed by annual audits. The license will also include a set amount of
consulting support. Licensees will also be required to participate in patent
maintenance and defense.

Certain transfers of IP to third parties may be licensing/royalty-based,
transaction-based, or other forms of transfer. Licensing/royalty-based fees
involve transfers in which the company earns the income over time, as a lump-
sum payment or the amount of income is not fixed or determinable until the
licensee sells future related products (i.e., variable royalty, based upon
licensee's revenue). Accordingly, following delivery and or legal conveyance
of rights to the aforementioned IP to the client, and following inception of
the license term, revenue is recognized in a manner consistent with the
nature of the transaction and the earnings process.

Combined License/Consulting Revenue - in certain circumstances the license
agreement will also include consulting services to facilitate the use of the
Company's IP, in which case the arrangement may include multiple deliver-
ables. If the client is dependent on the consulting services of the Company
to bring value to the license then the license and consulting services will
be considered a single unit of accounting. If, however, the license has value

  Accompanying Notes are an Integral Part of the Financial Statements    F 7

                                     21
<PAGE>
to the client, independent of the consulting services provided by the
Company, then each deliverable has value on a standalone basis. As such each
delivered item or items shall be considered a separate unit of accounting.

Alternatively, license terms may contain a citation of milestones of
achievement by the licensee. Each milestone may be tied to an increase in the
minimum royalty. For example, biomedical milestones may include completion of
animal trials, submission and then approval of 510K applications or pre-
market approval by the FDA. Each licensee pursuing a biomedical application
will be expected to develop its own clinical data to secure such pre-market
notification (510k) or approval. Under these circumstances, the deliverable,
or unit of accounting, consideration may be contingent on the substantive
achievement of one or more milestones. As such, revenue is recognized in its
entirety in the period in which the milestone is achieved.

During the years ended December 31, 2013, 2012 and 2011, the Company
recognized $2,350, $10,313, and $80,000, respectively, in revenue.

PROPERTY, PLANT AND EQUIPMENT:  Fixed Assets (land, buildings and equipment)
are carried at cost less accumulated depreciation. Depreciation is based on
the estimated service lives of depreciable assets and is provided using the
Modified Accelerated Cost Recovery System (MACRS) method. In the case of
disposals, assets and related depreciation are removed from the accounts,
and the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES:  The Company takes an asset and liability approach to financial
accounting and reporting for income taxes. The difference between the
financial statement and tax basis of assets and liabilities is determined
annually. Deferred income tax assets and liabilities are computed for those
differences that have future tax consequences using the currently enacted tax
laws and rates that apply to the periods in which they are expected to affect
taxable income. Valuation allowances are established, if necessary, to reduce
the deferred tax asset to the amount that will assure full realization. As of
December 31, 2012, the Company recorded a valuation allowance that reduced
its deferred tax assets to zero.

CONCENTRATIONS OF CREDIT RISK: Financial instruments which potentially
subject the Company to significant concentrations of credit risk consist
primarily of investment securities. Investment securities are exposed to
various risks, such as interest rate, market and credit risks. Due to the
level of risk associated with certain investment securities, it is reasonably
possible that changes in the values of investment securities can occur in the
near term and that each change could materially affect the amounts reported
in the financial statement.

GOING CONCERN: The Company is currently conducting operations. However, it
has not yet generated sufficient operating revenue to fund its development
activities to date. As such, the Company has have relied on funding by the
Company's President and the sale of its common stock. There is a substantial
doubt that the Company will generate sufficient revenues in future years to
meet its operating cash requirements. Accordingly, the Company's ability to
continue operations in the short-term depends on its success in obtaining
equity or debt financing in an amount sufficient to support its operations.
This could raise doubt as to its ability to continue as a going concern.
The financial statements do not include any adjustments that might result
from this uncertainty.

      Accompanying Notes are an Integral Part of the Financial Statements    F 8

                                       22
<PAGE>
NOTE B - INTELLECTUAL PROPERTY

Intellectual property protection is being pursued for the specifically
identifiable intellectual property (IP) termed Signal Advance technology. The
following table lists the patent applications and issued patents and their
respective status:

  Patent Office         Patent/Application No.   Status
  ------------------    ----------------------   ------------------
  United States         8452544                  Issued May 2013
  China                 ZL 200880015288.2        Issued Nov. 2012
  Europe                EP 08 75 4879.8	         Under examination
  Mexico                MX/A/2009/00921	         Under examination
  India                 3465/KOLNP/2009          Not yet examined

Additional patent submissions related to specific applications, SA circuit
configurations, and signal processing techniques are in preparation.

The IP derives from an assignment of the IP in the form of a patent application
filed with the USPTO as well as any patents which issue as a result of U.S. and
related international patent applications.

As ASSIGNEE, the Company is responsible for:

1) Funding and executing activities required for any regulatory approval,
    development, implementation and commercialization;
2) Introducing assigned products which incorporate the patent pending or
    patented technology to the commercial market;
3) Make its best efforts to:
     a) Develop and market assigned products and services, and
     b) Increase and extend the commercialization of assigned products, and
4) Commence the advertising and marketing assigned products not later than 24
    months following the granting of the patent

The assignment was privately negotiated between the Company's President, Dr.
Hymel (Assignor) and the remaining members of the board of directors for the
Company (Assignee). Consideration to acquire the IP rights, in the form of
equity (specifically 1,525,000 shares of SAI common stock, to date) was
expensed as the assignment is considered a transaction between entities under
common control. The value of the common stock issued in exchange for the equity
was based on the most recent private sales of stock. In addition, royalties are
payable to Assignor on net sales and/or license fees as follows: a) <$10M: 6%;
b) $10-$25M: 8%, and c)>$25M: 10%. Assignor's remedy for non-payment is the
termination of the assignment.












   Accompanying Notes are an Integral Part of the Financial Statements    F 9

                                     23
<PAGE>
The costs incurred in acquiring the assignment of the Signal Advance IP as well
as the pursuit of domestic and international patent and trademark protection are
expensed (included as "Intellectual Property" under expenses on the Statements
of Income and Retained Earnings (Accumulated Deficit)) for the years ended
December 31, 2013, 2011 and 2011. These costs include expenses to prepare and
prosecute patent applications and protect the IP, include filing, issuance and
renewal fees, expenses for consultants, experts, advisors, patent attorneys,
including foreign associates, patent applications, claims and other amendments,
responses to office actions, etc. Any patent infringement case may hinder the
Company's ability to generate revenues.


NOTE C - AVAILABLE FOR SALE SECURITIES

Cost and fair value of available for sale securities (acquired Jan. 10, 2011)
as of December 31, 2013 are as follows:
                                         Cost Gross   Gain(Loss)   Fair Value
                                         ----------   ----------   ----------
Equity Securities Available for Sale:      25,000      (24,487)        13


NOTE D - EQUIPMENT

Property and equipment as of December 31, 2013 and 2012 are summarized as
follows:
                                       2013          2012          2011
                                    ----------    ----------    ----------
  Fixed Assets (Cost/Basis)           125,807       123,783       122,772
  Less: Accumulated Depreciation     (121,884)     (119,117)     (113,885)
                                    ----------    ----------    ----------
  Net Book Value                    $   3,924     $   4,607     $   8,887

Depreciation expense in the years ended December 31, 2013, 2012 and 2011,
were $2,707, $5,292 and $8051, respectively.

NOTE E - INCOME TAXES

Operating Loss Carry-Forwards:  As of December 31, 2013, the Company has a
net operating tax loss carry-forward of $1,201,149. Other loss carry-forwards
from previous periods may be offset against future federal income taxes. If
not used, loss carry-forwards will expire as indicated in the following
table:
              Year   Operating Losses     Year   Operating Losses
              ----   ----------------     ----   ----------------
              2022        108,119         2028      1,443,756
              2023        104,123         2029        306,926
              2024        114,901         2030         32,146
              2025         52,988         2031        160,674
              2026        218,176         2032        179,372
              2027        256,471         2033      1,201,149

Deferred Tax Asset:  A valuation allowance was not recognized for the full
amount of the deferred tax asset because, based on the weight of available
evidence, it is more likely than not that some portion or the entire deferred
tax asset will not be realized.

   Accompanying Notes are an Integral Part of the Financial Statements   F 10

                                     24
<PAGE>
Tax Depreciation:  The Company uses the Modified Accelerated Cost Recovery
System (MACRS) for depreciation of property for tax purposes.


Note F - SHORT TERM LOAN

The President has loaned funds to the Company under the terms of a Line of
Credit Promissory Note negotiated with, and approved by, the Board of
Directors.


NOTE G - TRADE PAYABLE

The President of the Company has provided on-going services in exchange for
equity reflected by the trade payable. The terms of the conversion of the
debt to equity in was negotiated with, and approved by, the Board of
Directors.


NOTE H - FACILITIES LEASE

The Company currently leases office space, from its president, on a month to
month basis at a rate of $700 per month. The following is a schedule of
future minimum payments for 4 years under the above operating lease as of
the year ended December 2013.
                                           Year      Amount
                                           ----     -------
                                           2014     $ 8,400
                                           2015       8,400
                                           2016       8,400
                                           2017       8,400

                                Four Year Total:    $33,600

Rental expense amounted to $8,400 for the years ended December 30, 2013, 2012
and 2011.


Note J - REVERSE STOCK SPLIT

In July, 2011 (following approval by the Shareholders in May, 2011) the
Board of Directors voted to affect a four for one (4/1) reverse split of
its common shares and a 'Resolution Relating to a Series of Shares' was
submitted to the Texas Secretary of State, pursuant to The Texas Business
Organizations Code, Section 21.115. The reverse split became effective on
September 1, 2011. Fractional shares were rounded up to whole shares. Prior
to the reverse split, the common stock shares issued and outstanding totaled
32,603,325. As of December 31, 2011, following the four for one (4/1) reverse
split, 8,111,409 shares of common stock were issued and outstanding.







   Accompanying Notes are an Integral Part of the Financial Statements   F 11

                                     25
<PAGE>

                          SUPPLEMENTAL INFORMATION

                            Signal Advance, Inc.
          Schedules of General, Selling and Administrative Expenses
                 Years Ended December 31, 2013, 2012, 2011


                                       2013         2012         2011
                                     --------     --------     --------
           Automobile Expense          3,411        2,066           87
           Bank Service Charges          123          112           94
           Dues and Subscriptions         45           37          100
           Education/Training              0            7        2,969
           Employee Benefits           4,078        4,683        2,661
           Fees/Licenses               1,168            0          351
           Insurance                     722          422            0
           Interest Expense            8,901        2,704        3,942
           Maintenance and Repairs       824          872          759
           Marketing/Advertising         500          650          650
           Meals/Entertainment         1,007          389          281
           Office Supplies               505          266          120
           Postage and Delivery          143          192          249
           Rent                        8,400        8,400        8,400
           Taxes                          50          100            0
           Telephone                   1,520        1,755        3,995
           Travel                     10,319        5,361        6,701
           Utilities                   2,560        2,222        2,676
                                     ========     ========     ========
           Total Expense              44,274       30,239       34,034

























               See Accompanying Notes and Accountant's Report            F 12

                                     26
<PAGE>
Item 9. Changes In and Disagreements with Accountants on Accounting and
        Financial Disclosure

None.


Item 9A(T). Controls and Procedures

MANAGEMENT'S REPORT ON DISCLOSURE CONTROLS AND PROCEDURES:  Management is
responsible for establishing and maintaining adequate internal control over
financial reporting (as defined in Exchange Act Rule 13a-15(f)). Internal
control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the prep-
aration of financial statements for external purposes in accordance with
accounting principles generally accepted in the United States of America.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that
compliance with the policies or procedures may deteriorate. Management
evaluated the effectiveness of the Company's internal control over financial
reporting as of December 31, 2013 using the criteria established in 'Internal
Control - Integrated Framework' issued by the Committee of Sponsoring
Organizations of the Treadway Commission ("COSO").

A material weakness is a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the Company's annual or interim
financial statements will not be prevented or detected on a timely basis. In
its assessment of the effectiveness of internal control over financial
reporting as of October 31, 2013, based on the above referenced guidelines,
the Company determined that there were control deficiencies that constituted
material weaknesses, as described below.

1) We do not have an Audit Committee - While not being legally obligated to
   have an audit committee, it is the management's view that such a
   committee, including a financial expert member, is an important entity
   level control over the Company's financial statement. Currently the Board
   of Directors acts in the capacity of the Audit Committee, and does not
   include a member that is considered to be independent of management to
   provide the necessary oversight over management's activities.

2) We did not maintain appropriate cash controls - As of December 31, 2013,
   the Company has not maintained sufficient internal controls over financial
   reporting for the cash process, including failure to segregate cash
   handling and accounting functions, and did not require dual signature on
   the Company's bank accounts. Alternatively, the effects of poor cash
   controls were mitigated by the fact that the Company had limited
   transactions in their bank accounts.

3) We did not implement appropriate information technology controls - As at
   December 31, 2013, the Company retains copies of all financial data and
   material agreements and periodically make backups of the Company's data;
   however there is no formal procedure or evidence of normal backup of the
   Company's data or off-site storage of data in the event of theft,
   misplacement, or loss due to unmitigated factors.


                                     27
<PAGE>
Accordingly, the Company concluded that these control deficiencies resulted
in a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely
basis by the company's internal controls.  As a result of the material
weaknesses described above, management has concluded that the Company did
not maintain effective internal control over financial reporting as of
December 31, 2013 based on criteria established in Internal Control -
Integrated Framework issued by COSO.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING:  There has been no
change in our internal control over financial reporting identified in
connection with our evaluation we conducted of the effectiveness of our
internal control over financial reporting as of December 31, 2013, that
occurred subsequent to the evaluation that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.

This annual report does not include an attestation report of the Company's
registered public accounting firm regarding internal control over financial
reporting. Management's report was not subject to attestation by the
Company's registered public accounting firm pursuant to rules of the SEC
applicable to an Emerging Growth Company  that permit the Company to provide
only management's report in this annual report.




































                                     28
<PAGE>
                                  PART III

Item 10. Directors, Executive Officers, Promoters and Control Persons of the
Company

DIRECTORS AND EXECUTIVE OFFICERS: The following table sets forth the names,
positions and ages of the current SAI Directors and Officers. Directors are
elected during the annual shareholders' meeting and serve for one year and
until their successors are elected and qualify. Officers are elected by our
board of directors and their terms of office are at the discretion of our
board. There are no family relationships among our directors, executive
officers, director nominees or significant employees. Two of our Directors
are independent per NASDAQ listing standards.

      Director/Officer   Age    Position/Office
      ----------------   ---    -----------------------------
      Chris Hymel         55    Director, President/Treasurer
      Malcolm Skolnick    78    Director, Secretary
      Ron Stubbers        51    Director, Vice-President
      Richard Seltzer     58    Director
      Karl Zercoe         49    Director

All directors hold office until the next annual meeting of the shareholders
of the Company and until their successors have been duly elected and
qualified. The Company's Bylaws provide that the Board of Directors will
consist of no less than three members.

BIOGRAPHIES:

Chris M. Hymel, Ph.D. (President/Treasurer, Director): served as a director
and its President and Treasurer since its inception. Dr. Hymel previously
founded a computer systems/networking consulting and development firm and,
later, a medical-legal firm which developed over 60 animations used in liti-
gation support.  He also served on the board of a non-profit corporation
through 2009. Professional experience also includes technology development at
the University of Texas, Neurophysiology Research Center, including the
development of proprietary neurostimulation, signal generation and data
acquisition systems, and control systems engineering for Shell Oil & Shell
Development Companies and Johnson Controls, Inc. Dr. Hymel holds a doctorate
in biomedical sciences from the University of Texas Health Science Center,
Houston as well as bachelors and masters degrees in electrical engineering
from Texas A&M University. Dr. Hymel holds multiple patents and has authored
a number of scientific / technical publications. Dr. Hymel developed the
propietary Signal Advance technology and successfully demonstrated temporally
advanced detection of a range of analog (including bioelectric) signals in
his doctorate research completed at the University of Texas Health Science
Center in August 2010.

Malcolm Skolnick (Secretary, Director):  Dr. Skolnick received his Ph.D. in
physics from Cornell University and J.D. from the University of Houston Law
Center. He retired in 2008 after ten years as a Director, President/CEO of
CytoGenix, Inc., a publicly traded, development stage biotechnology firm in
Houston Texas. Prior to joining CytoGenix, Dr. Skolnick, a tenured professor,
held academic positions in the Medical School, the Graduate School of
Biomedical Sciences and the School of Public Health of the University of
Texas Health Science Center (UTHSC), Houston. In addition to his service as a
Department Chair in the Medical School and professorial duties, Dr. Skolnick

                                     29
<PAGE>
directed the UTHSC Office of Technology Management, overseeing the Univer-
sity's activities in protecting and licensing its technology portfolio. He
also headed the Neurophysiology Research Center and served as the principal
investigator of several clinical trials in pain management, smoking cessation
and reduction of withdrawal symptoms in drug addiction. Dr. Skolnick also
serves as Director and Vice President of the Southwest Health Technology
Foundation, Resolution Forum, Inc., Responsible Community Design Internation-
al, Inc., and Hudson Forest Homeowners' Association. He has served as an
expert witness in intellectual property, product liability, and accident
reconstruction matters. Dr. Skolnick is a registered patent attorney,
patented inventor and is licensed to practice law in the State of Texas. In
addition to his service on various corporate boards, since his retirement
from CytoGenix, Inc., he has been active in patent prosecution and licensing
for selected clients and has been an invited lecturer at several local
universities.

Ron A, Stubbers (Vice-President, Director): Mr. Stubbers has been developing
and manufacturing electronic biomedical devices for over 20 years, much of it
while VP of Engineering and VP of Operations for Neuroscan, Inc. and its suc-
cessor Compumedics, USA from 1991-2003, and aDEPtas, Inc. and its successor
InGeneron, Inc. from 2004-Present. His experience includes development and
production of medical devices ranging from neurostimulation systems to EEG
acquisition and analysis systems. He has also worked in the areas of product
design and manufacturing engineering, quality, regulatory and technical sup-
port for startup companies. Mr. Stubbers has managed corporate ISO/EN/QSR
quality management systems requirements and compliance and European CE and
FDA 510K Class II as well as other regulatory approvals for world-wide
medical device distribution. Mr. Stubbers received his bachelor's degree in
electrical engineering from the University of Idaho in 1985, completed
graduate coursework at the University of Texas, Graduate School of Biomedical
Sciences and at Rice University, and completed his MBA at the University of
Houston (2013).

Richard C. Seltzer (Director):  Mr. Seltzer received his J.D. from South
Texas College of Law in 1981 and his LL.M. in Taxation from the University of
Florida in 1982. Mr. Seltzer has been in private practice for more than
thirty years representing both established and startup businesses in mergers
and acquisitons, financial and tax issues, contractual matters, shareholder
disputes, real estate acquisitions and general business litigation in Texas
State Courts. His practice includes arranging viable capital infusions for
ongoing businesses, negotiating business and real estate related contracts.
He has handled the licensing of proprietary information for a non-profit
organization in Texas. He also continues to successfully represent numerous
taxpayer corporations and individuals before the Internal Revenue Service,
including both its Appellate and Collection Divisions as well as representing
taxpayers for matters filed with the U.S. Tax Court. For more than fifteen
years Mr. Seltzer has been a frequent invited speaker covering general
business topics at the People's Law School in conjunction with the University
of Houston Law School. He is also an approved mediator in the State of Texas
having received his certification in 2008.

Mr. Seltzer has continued to serve as a member of the Board of Directors of
Bridges to Life, a nonprofit organization in Houston, since 2003. He was
appointed in 2011 as a member of the Board of Directors of STARBASE, Inc., a
federally funded educational program working in conjunction with the Department
of Defense and the National Guard that works with upper elementary school

                                     30
<PAGE>
students particularly interested in math, science, engineering and technology
related programs. In addition, Mr. Seltzer serves on the Boards of Directors
of the following Texas corporations: Atlas Management, Inc. (appointed in
2000), Innovative Tooling and Accessories, Inc. (appointed in 2007),
Intuitec, Inc. (appointed in 2003), Milsob Properties, Inc. (appointed in
2008). He has also served on the Board of Directors of Delta Shaver Company,
Inc., a Delaware corporation since 2011.

Karl Zercoe (Director):  Mr. Zercoe, a computer programmer and experienced
entrepreneur, has been designing and implementing software applications
since 1986. He founded Titanium Software, Inc. in 1996 and is currently the
Director, President and Owner. In 2003 his firm focused on an application for
electronic medical records and scheduling for college counseling centers. As
of 2012, their software, Titanium Schedule, is the market leader with 700+
installations in 11 countries. Mr. Zercoe has a B.S. in computer science with
a minor in mechanical engineering from Texas A&M University.

AUDIT COMMITTEE:  We do not have an audit committee financial expert, as the
cost of retaining a financial expert at this time is prohibitive. Further,
our President has the requisite financial experience/knowledge, thus, we
believe the services of a financial expert are not currently warranted.

SIGNIFICANT EMPLOYEES:  We have no employees other than our directors and
officers of which only the President/Treasurer devotes full time to company
matters. Others devote time as needed. We intend to hire staff as needed.

FAMILY RELATIONSHIPS: None


Item 11. Executive Compensation

We are providing compensation disclosure that satisfies the requirements
applicable to emerging growth companies, as defined in the JOBS Act. The
summary compensation table below shows certain compensation information paid for
services rendered in all capacities to us by our principal executive officer and
by each other executive officer whose total annual salary and bonus exceeded
$100,000 during years ending December 31, 2012 and 2011 and 2013. Other than as
set forth below, no executive officer's total annual compensation exceeded
$100,000 during our last fiscal period.

SUMMARY COMPENSATION TABLE:
<TABLE>
<CAPTION>
<S>          <C>           <C>      <C>     <C>     <C>       <C>      <C>             <C>            <C>           <C>
                                                                                       Non-Qualified
                                                    Stock              Non-Equity      Deferred       All Other
                           Year or                  Awards    Options  Incentive Plan  Compensation   Compensation
Name         Position      Period   Salary  Bonus    (1)      Awards   Compensation    Earnings           (2)       Total
-----------  ----------    -------  ------  ------  --------  -------  --------------  -------------  ------------  --------
Chris Hymel  Pres/Treas      2011     -0-     -0-   $120,000    -0-          -0-            -0-            $5,630   $125,630

Chris Hymel  Pres/Treas      2012     -0-     -0-   $108,000    -0-          -0-            -0-            $4,683   $112,683

Chris Hymel  Pres/Treas      2013     -0-     -0-   $108,000    -0-          -0-            -0-            $4,078   $112,078

</TABLE>
  (1) Non-cash compensation: Equity issued for services rendered
  (2) Reimbursement of medical and professional development expenses

                                     31
<PAGE>

SAI entered into a consulting agreement with Dr. Chris M. Hymel, the Company
President, whereby his annual compensation was $120,000 per year in 2011 and
108,000 per year in 2012 and 2013, plus limited reimbursement of professional
development and medical expenses. Dr. Hymel is expected to devote essentially
full-time (at least 40 hours/week) on activities related to the Company. The
term of the agreement is year-to-year but may be terminated by giving one
month's notice. Eligible medical and professional development expenses are
either paid or reimbursed in cash and annual compensation for services
rendered has been in the form of equity, specifically common stock.

In years ending December 31, 2011, 2012 and 2013, Dr Skolnick received
$20,000, $15,000 and $5,000, respectively, in the form of equity (common
stock) in exchange for services, the majority of which was related to
intellectual property protection. Other than as described above, all other
directors and executive officers received well under less than $10,000
compensation in the same periods, also in the form of equity (common stock)
in exchange for their services. No executive officers received a bonus or
deferred compensation.

Other Executive Officer Compensation (to date):

   Outstanding Equity Awards:                   None
   Option Exercises/Stock Vested Table:         None
   Pension Benefits Table:                      None
   Non-qualified Deferred Compensation Table:   None
   All Other Compensation Table:                None
   Perquisites Table:                           None

There are no employment contracts, compensatory plans or arrangements (except
as referenced above for the Company President), including payments to be
received from the Company with respect to any executive officer or director
of the Company which would in any way result in payments to any such person
because of his or her resignation, retirement or other termination of employ-
ment with the Company or its subsidiaries, any change in control of the
Company or a change in the person's responsibilities following a change in
control of the Company. Nor are there any agreements or understandings for
any director or officer to resign at the request of another person. None of
the Company's directors or executive officers is acting on, or will act, at
the direction of any other person.

COMPENSATION PURSUANT TO PLANS:  There is no retirement, pension, profit
sharing, or other plan covering any of our officers and directors. The
Company has adopted no formal stock option plans for our officers, directors
and/or employees. SAI reserves the right to adopt one or more stock options
plans in the future. Presently, there is no plan to issue additional equity
in the Company or options to acquire the same to our officers, directors or
their affiliates or associates except for compensation of Director and
Officers as described previously.

CORPORATE GOVERNANCE:  Currently, the Company has no formal Audit or
Compensation Committee.






                                     32
<PAGE>
Item 12. Security Ownership of Certain Beneficial Owners and Management
         and Related Stockholder Matters

The Company is authorized to issue 100,000,000 shares of common stock, with
no par value. Holders of common stock are entitled to one vote per share on
all matters subject to shareholder vote. The common stock has no cumulative,
preemptive or other subscription rights. All of the presently issued shares
of common stock are fully paid and non-assessable. The Board of Directors
may declare dividends payable to holders of common stock out of legally
available funds. If the Company is liquidated or dissolved, holders of shares
of common stock will be entitled to share ratably in any assets of the
Company remaining after satisfaction of all of its liabilities.

As of December 31, 2013, 9,520,409 shares had been issued to 171 sharehold-
ers. The following table sets forth the number of shares of common stock that
are beneficially owned as of December 31, 2013 by (i) each person known by us
to be the beneficial owner of more than 5% of the outstanding shares of our
common stock, (ii) each of our directors and executive officers, (iii) all
officers and directors as a group and (iv) all officers and directors and
each person known by us to be the beneficial owner of more than 5% of the
outstanding shares of our common stock as a group. The persons and entities
named in the table have sole voting and sole investment power with respect
to the shares set forth opposite the stockholder's name, subject to
community property laws, where applicable.

                                                    Amount/Nature
                                          Title     of Beneficial  Percent
Name of Beneficial Owner                  of Class  Ownership(1)   of Class
--------------------------------------    --------  -------------  --------
Chris Hymel, Director/Officer(2,4)        Common      4,390,013      46.4%
Ray and Tricia Corkran(3,4)               Common        821,250       8.7%
Malcolm Skolnick, Director/Officer(2,4)   Common        291,834       3.1%
Ron Stubbers, Director/Officer(2,4)       Common        261,250       2.8%
Karl Zercoe, Director(2,4)                Common        256,250       2.7%
Richard C. Seltzer, Director(2)           Common         98,000       1.0%

Officers/Directors as a group             Common      5,297,347      56.0%
   (5 total)
Officers/Directors, >5% Shareholders      Common      6,111,597      64.4%
   (6 total)

(1) Beneficial ownership is determined in accordance with SEC rules, and
     includes any shares as to which the stockholder has sole or shared voting
     power or investment power. The indication herein, regarding beneficial
     ownership, is not an admission, on the part of the stockholder, that he,
     she or it is a direct or indirect beneficial owner of those shares.
(2) The address for all Directors/Officers: 2520 CR 81, Rosharon, TX  77583
(3) The address for the Corkrans: 321 Grand Ranch Lane, Friendswood, TX 77546
(4) Includes shares held by spouses and minor children.
(5) The percent of class is based on 9,520,409 shares of common stock issued
     and outstanding as of the date of this annual report.






                                       32
<PAGE>
Item 13. Certain Relationships and Related Transactions, and Director
         Independence

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS:

The Company owes its President, Chris M Hymel, $118,406 as of December 31,
2013, in the form of an unsecured loan. The note is due on demand and
carries a simple interest of 2.5% per quarter.  The Company currently leases
office space, from its president, on a month to month basis at a rate of $700
per month. The Company obtained rights to the intellectual property though an
assignment agreement with its President (discussed in greater detail in Note
B - Intellectual Property on Page XX (F8, of the Financial Statements and
Supplementary Information).

Other than the President's compensation and related transactions, discussed
previously, since the company's inception, there has not been, nor is there
currently proposed, any transaction or series of similar transactions with
related parties to which the Company was or will be a party:

  1) In which the amount involved exceeds $120,000; and
  2) In which any director, executive officer, shareholder who beneficially
      owns 5% or more of SAI common stock, or any member of their immediate
      family, had or will have a direct or indirect material interest.

DIRECTOR INDEPENDENCE The Company has not established its own definition for
determining whether its directors and nominees for directors are 'indepen-
dent' nor has it adopted any other standard of independence employed by any
national securities exchange or inter-dealer quotation system. However, as
determined by the NASDAQ listing standards, one of the Company's current
directors, Mr. Zercoe, is considered independent as he is not an Officer of
the Company, receives no compensation for services other than as a director
and owns less than 5% of the issued and outstanding shares of the Company.


Item 14. Principal Accountant Fees and Services

During fiscal year ended December 31, 2013, we incurred approximately $13,198
in fees to our principal independent accountants for professional services
rendered in connection with the audit of our financial statements and
supplementary information for years ended December 2013, 2012 and 2011 and
for the reviews of for the quarters ended September 31, 2013 and 2012, June
30, 2012 and 2013 and March 30, 2013 and 2012.

                                  PART IV
Item 15. Exhibits

The following exhibits are filed as part of this Annual Report.

Exhibit 31.1:  Certification of Chief Executive Officer pursuant to Section
               302(a) of the Sarbanes-Oxley Act

Exhibit 31.2:  Certification of Chief Financial Officer pursuant to Section
               302(a) of the Sarbanes-Oxley Act

Exhibit 32.1:  Certification of Chief Executive Officer and Chief Financial
               Officer under Section 1350 as Adopted Pursuant Section 906 of
               the Sarbanes-Oxley Act

                                     33
<PAGE>
SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.



Dated: March 17, 2014
SIGNAL ADVANCE, INC.


                                       By: /s/ Chris M. Hymel




                                        Chris M. Hymel, President/Treasurer

Pursuant to the requirements of the Securities Act of 1933, this Registration
Statement has been signed by the following persons in the capacities and as
of the dates indicated.

SIGNATURE                 TITLE                               DATE
-----------------------   -------------------------------     ---------------

/s/ Chris M. Hymel        Member, Board of Directors,         March 17, 2014
Chris M. Hymel            President and Treasurer
                          (Principal Executive, Financial
                           and Accounting Officer)


/s/ Malcolm H. Skolnick   Member: Board of Directors,         March 17, 2014
Malcolm H. Skolnick       Secretary


/s/ Richard C. Seltzer    Member of the Board of Directors    March 17, 2014
Richard C. Seltzer





























                                     34
<PAGE>
Supplemental Information to be Furnished With Reports Filed Pursuant to
Section 15(d) of the Act by Registrants Which Have Not Registered Securities
Pursuant to Section 12 of the Act


As of the date of filing of this report, no annual report or proxy material
has been sent to security holders. An annual report and/or proxy material
will be furnished to security holders subsequent to the filing of the annual
report of this Form and the registrant shall furnish copies of such material
to the Commission when it is sent to security holders.















































                                     35
<PAGE>